The purpose of this webpage and subsequent document is to provide information to existing and prospective investors, and potential commercial partners, about the current status of BCAL’s research and development. It is not intended to promote the use or supply of any therapeutic goods.
4 March 2024 Final Director's Interest Notice
4 March 2024 Initial Director's Interest Notice
ASX Announcements
29 February 2024 BCAL Strengthens Board with Appointment of Commercial NED
30 January 2024 Quarterly Activities/Appendix 4C Cash Flow Report
29 November 2023 Collaboration with KIMS & Indo-American Hospitals Hyderabad
6 November 2023 BCAL Files Further Foundational Patent Application
31 October 2023 Quarterly Activities/Appendix 4C Cash Flow Report
11 September 2023 BCAL Locks Down Crucial Breast Cancer Signature
4 September 2023 Shane Ryan Appointed Chief Operating Officer
1 September 2023 Cleansing Notice
1 September 2023 Application for quotation of securities - BDX
30 August 2023 Preliminary Final Report
30 August 2023 Share Purchase Plan Offer Booklet
29 August 2023 Proposed issue of securities - BDX
28 August 2023 $2.4m Capital Raise to Further BREASTEST Commercialisation
24 August 2023 Investor Presentation
24 August 2023 ASX Announcement - Trading Halt
8 August 2023 BCAL Investor Education Update & Webinar
2 August 2023. Breakthrough Results a Major Step Towards Commercialisation
28 July 2023
ASX Announcement. Read more.
28 July 2023
ASX Announcement. Read more
27 July 2023
20 July 2023
Shareholder newsletter. Read more.
30 June 2023
ASX Announcement. Read more.
30 June 2023
ASX Announcement. Read more.
6 June 2023
16 May 2023
BCAL appoints David Darling as an advisor. Read more.
11 May 2023
ASX Announcement. Read more.
3 May 2023
ASX Announcement. Read more.
3 May 2023
16 Jan 2023
ASX Announcement. Read more
24 Apr 2023
ASX Announcement. Read more
7 Feb 2022
Recent Analysis Significantly Improves Commercial Prospects. Read more
25 October 2022
Establishment of Development & Clinical Services Laboratory. Read more
28 June 2022
BCAL Enters US Product Development Agreement with Precion. Read more
12 May 2022
BCAL Files Foundational Patent Application. Read more
24Mar 2022
Shareholder Newsletter. Read more
8 Feb 2022
7 February Announcement - Additional Information. Read more
15 Nov 2022
Shareholder Newsletter. Read more
BCAL Presentation Accepted for 2022 ASCO Annual Meeting. Read more
11 Jan 2022
3 Nov 2021
21 Oct 2021
3 Sep 2021
Dr John Hurrell Appointed Chief Executive Officer. Read more
Strong Cohort 4 Testing Data Demonstrates Value of BCAL Test. Read more
Notice of Annual General Meeting and Explanatory Statement. Read more
Australian Clinical Studies Launched. Read more